ArticleCancers2019
Development of DNA Aptamers to Native EpCAM for Isolation of Lung Circulating Tumor Cells from Human Blood.
Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Advances in Aptamer Diagnostics Targeting Non-Small-Cell Lung Cancer: A Systematic Review.International journal of molecular sciences · 2026Pooled it
- Monitoring of breast cancer progression via aptamer-based detection of circulating tumor cells in clinical blood samples.Frontiers in molecular biosciences · 2023Article
- Recent advances in aptamer applications for analytical biochemistry.Analytical biochemistry · 2022Article
- Application of Microfluidics in Detection of Circulating Tumor Cells.Frontiers in bioengineering and biotechnology · 2022Review
- The Potential of Aptamer-Mediated Liquid Biopsy for Early Detection of Cancer.International journal of molecular sciences · 2021Review
- New Biomarkers in Cancers.Cancers · 2021Article
- Targeting Strategies for Enhancing Paclitaxel Specificity in Chemotherapy.Frontiers in cell and developmental biology · 2021Review
- Advances in Oligonucleotide Aptamers for NSCLC Targeting.International journal of molecular sciences · 2020Review
- Cancer Stem Cells-Origins and Biomarkers: Perspectives for Targeted Personalized Therapies.Frontiers in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We selected DNA aptamers to the epithelial cell adhesion molecule (EpCAM) expressed on primary lung cancer cells isolated from the tumors of patients with non-small cell lung cancer using competitive displacement of aptamers from EpCAM by a corresponding antibody. The resulting aptamers clones showed good nanomolar affinity to EpCAM-positive lung cancer cells. Confocal microscopy imaging and spectral profiling of lung cancer tissues confirmed the same protein target for the aptamers and anti-EpCAM antibodies. Furthermore, the resulted aptamers were successfully applied for isolation and detection of circulating tumor cells in clinical samples of peripheral blood of lung cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.